William Blair Investment Management LLC Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

William Blair Investment Management LLC raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,597,698 shares of the biopharmaceutical company’s stock after purchasing an additional 14,736 shares during the quarter. William Blair Investment Management LLC owned 0.05% of Amicus Therapeutics worth $146,930,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in FOLD. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Amicus Therapeutics in the third quarter valued at $55,000. R Squared Ltd purchased a new stake in Amicus Therapeutics in the fourth quarter valued at $79,000. KBC Group NV raised its holdings in shares of Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 3,120 shares during the period. Stephens Inc. AR purchased a new stake in shares of Amicus Therapeutics in the 4th quarter valued at $101,000. Finally, AlphaQuest LLC raised its holdings in shares of Amicus Therapeutics by 635.1% in the 4th quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 9,272 shares during the period.

Wall Street Analysts Forecast Growth

FOLD has been the topic of several research analyst reports. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Trading Up 1.0 %

NASDAQ:FOLD opened at $8.90 on Monday. The business’s 50-day moving average is $9.38 and its two-hundred day moving average is $10.14. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a 12 month low of $8.55 and a 12 month high of $12.65. The firm has a market capitalization of $2.73 billion, a PE ratio of -49.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.